Announcement on Subsidiary's Drug Obtaining Drug Registration Certificate

Wanbangde Pharmaceutical Holding Group Co., Ltd.·July 27, 2026·2 pages

✨ AI Summary

This announcement details that the company's wholly-owned subsidiary, Wanbangde Pharmaceutical, has received a Drug Registration Certificate from the NMPA for Sulpiride Tablets. This approval signifies the drug meets registration requirements and is considered equivalent to passing the generic drug quality and efficacy consistency evaluation. The drug is also included in the 2025 National Medical Insurance Catalog and the 2026 National Essential Drug List.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002082

Stock Abbreviation: ST Wanbang

Announcement Number: 2026-058

Wanbangde Pharmaceutical Holdings Group Co., Ltd.

Announcement on Subsidiary's Drug Obtaining Drug Registration Certificate

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.

Wanbangde Pharmaceutical Holdings Group Co., Ltd. (hereinafter referred to as the "Company") announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Wanbangde Pharmaceutical"), recently received from the National Medical Products Administration the approved and issued "Drug Registration Certificate" for Sulpiride Tablets (hereinafter referred to as "this product"). The main contents are hereby announced as follows:

I. Basic Information of the Registration Certificate

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.